Thyroid Cancer in Children

McClellan, 1996, Thyroid cancer in children, pregnant women, and patients with Graves' disease, Endocrinol Metab Clin North Am, 25, 27, 10.1016/S0889-8529(05)70311-X Fenton, 2000, Autoantibodies to p53 in sera of patients with autoimmune thyroid disease, Ann Clin Lab Sci, 30, 179 Fenton, 2000, The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults, Thyroid, 10, 349, 10.1089/thy.2000.10.349 Fenton, 2000, The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults, J Clin Endocrinol Metab, 85, 1170, 10.1210/jc.85.3.1170 Fenton, 1999, Ras mutations are uncommon in sporadic thyroid cancer in children and young adults, J Endocrinol Invest, 22, 781, 10.1007/BF03343644 Patel, 2000, Tyrosine kinase expression is increased in papillary thyroid carcinoma of children and young adults, Front Biosci, 5, A1, 10.2741/Patel Tuttle RM, Patel A, Francis G, et al. Vascular endothelial growth factor (VEGF) and Type 1 VEGF receptor (Flt-1) are highly expressed in Russian papillary thyroid carcinomas. Paper presented at the 12th International Thyroid Congress. Kyoto (Japan), October 22–27, 2000. Tuttle RM, Fenton C, Lukes Y, et al. Activation of the ret/PTC oncogene in papillary thyroid cancer from Russian children exposed to radiation following the Chernobyl accident. Paper presented at: 12th International Thyroid Congress. Kyoto (Japan), October 22–27, 2000. Fenton CPA, Burch HB, Tuttle RM, et al. Nuclear localization of thyroid transcription factor-1 correlates with serum thyrotropin activity and may be increased in differentiated thyroid carcinomas with aggressive clinical course. Ann Clin Lab Sci 2001 2001;31:245–52. Ramirez, 2000, Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma, Clin Endocrinol (Oxf), 53, 635, 10.1046/j.1365-2265.2000.01124.x Straight, 2002, Thyroid carcinomas that express telomerase follow a more aggressive clinical course for children and adolescents, J Endocrinol Invest, 25, 302, 10.1007/BF03344009 Tuttle, 2002, Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short term TSH stimulation, J Clin Endocrinol Metab, 87, 1737, 10.1210/jc.87.4.1737 Patel, 2002, Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents, Pediatr Res, 52, 737, 10.1203/00006450-200211000-00021 Eccles, 2003, Erythropoietin and the erythropoietin receptor are expressed by papillary thyroid carcinoma from children and adolescents: expression of erythropoietin receptor might be a favorable prognostic indicator, Ann Clin Lab Sci, 33, 411 Shah, 2002, Intense expression of the b7-2 antigen presentation coactivator is an unfavorable prognostic indicator for differentiated thyroid carcinoma of children and adolescents, J Clin Endocrinol Metab, 87, 4391, 10.1210/jc.2002-011262 Patel, 2002, Nitrotyrosine, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents, J Endocrinol Invest, 25, 675, 10.1007/BF03345100 Patel, 2002, Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents, J Endocrinol Invest, 25, 403, 10.1007/BF03344028 Gydee, 2004, Differentiated thyroid carcinomas from children and adolescents express insulin-like growth factor-1 (IGF-1) and the IGF-1 receptor (IGF-1-R): cancers with the most intense IGF-1-R expression may be more aggressive, Pediatr Res, 55, 1 Costello, 2005, Thyroid cancers express CD-40 and CD-40 ligand: cancers that express CD-40 ligand may have a greater risk of recurrence in young patients, Thyroid, 15, 105, 10.1089/thy.2005.15.105 Yates, 2006, Erythropoietin in thyroid cancer, J Endocrinol Invest, 29, 320, 10.1007/BF03344103 Penko, 2005, BRAF mutations are uncommon in papillary thyroid cancer of young patients, Thyroid, 15, 320, 10.1089/thy.2005.15.320 Gupta, 2001, Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults, J Clin Endocrinol Metab, 86, 1346, 10.1210/jc.86.3.1346 Loh, 1999, Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma, J Clin Endocrinol Metab, 84, 458, 10.1210/jc.84.2.458 Patel A, Fenton C, Dogra S, et al. Infiltration of childhood thyroid carcinoma by proliferating lymphocytes is associated with increased expression of the FAS receptor and the Bax Pro-apoptotic peptide. Paper presented at the Endocrine Society. San Francisco (CA), June 19–22, 2002. Modi, 2003, Papillary thyroid carcinoma from children and adolescents contain a mixture of lymphocytes, J Clin Endocrinol Metab, 88, 4418, 10.1210/jc.2003-030342 Hung, 2002, Current controversies in the management of pediatric patients with well- differentiated nonmedullary thyroid cancer: a review, Thyroid, 12, 683, 10.1089/105072502760258668 Cooper, 2006, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 16, 109, 10.1089/thy.2006.16.109 SEER. Surveillance, epidemiology and end results. nih.gov. 2002. Feinmesser, 1997, Carcinoma of the thyroid in children: a review, J Pediatr Endocrinol Metab, 10, 561, 10.1515/JPEM.1997.10.6.561 Wartofsky, 2000, The thyroid nodule, 3 Rallison, 1975, Thyroid nodularity in children, JAMA, 233, 1069, 10.1001/jama.1975.03260100039017 Moretti, 2000, Molecular pathogenesis of thyroid nodules and cancer, Baillieres Best Pract Res Clin Endocrinol Metab, 14, 517, 10.1053/beem.2000.0101 LaQuaglia, 2000, Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases: a report from the Surgical Discipline Committee of the Children's Cancer Group, J Pediatr Surg, 35, 955, 10.1053/jpsu.2000.6935 Boulad, 1995, Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation, Bone Marrow Transplant, 15, 71 Sklar, 2002, Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study, J Clin Endocrinol Metab, 87, 3136, 10.1210/jc.87.7.3136 Kebebew, 2000, Differentiated thyroid cancer: “complete” rational approach, World J Surg, 24, 942, 10.1007/s002680010165 Tamimi, 2002, The association between chronic lymphocytic thyroiditis and thyroid tumors, Int J Surg Pathol, 10, 141, 10.1177/106689690201000207 Holm, 1985, Cancer risks in patients with chronic lymphocytic thyroiditis, N Engl J Med, 312, 601, 10.1056/NEJM198503073121001 Hung, 1992, Nodular thyroid disease and thyroid carcinoma, Pediatr Ann, 21, 50, 10.3928/0090-4481-19920101-09 Hung, 1999, Solitary thyroid nodules in 93 children and adolescents: a 35-years experience, Horm Res, 52, 15, 10.1159/000023426 Hagag, 1998, Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules, Thyroid, 8, 989, 10.1089/thy.1998.8.989 Corrias, 2001, Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches, J Clin Endocrinol Metab, 86, 4644, 10.1210/jc.86.10.4644 Gharib, 1994, Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect, Mayo Clin Proc, 69, 44, 10.1016/S0025-6196(12)61611-5 Gharib, 1993, Fine-needle aspiration biopsy of the thyroid: an appraisal, Ann Intern Med, 118, 282, 10.7326/0003-4819-118-4-199302150-00007 Gharib, 1995, Fine-needle aspiration biopsy: use in diagnosis and management of pediatric thyroid diseases, Endocr Pract, 1, 9, 10.4158/EP.1.1.9 James, 1991, The thyroid, vol 1, 507 De Nicola, 2005, Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasms, J Ultrasound Med, 24, 897, 10.7863/jum.2005.24.7.897 Orija, 2004, Management of nondiagnostic thyroid fine-needle aspiration biopsy: survey of endocrinologists, Endocr Pract, 10, 317, 10.4158/EP.10.4.317 Ahn, 1997, Telomerase activity and its clinicopathological significance in gastric cancer, Eur J Cancer, 33, 1309, 10.1016/S0959-8049(97)00113-5 Haugen, 1997, Telomerase activity in benign and malignant thyroid tumors, Thyroid, 7, 337, 10.1089/thy.1997.7.337 Lerma, 2005, Telomerase activity in “suspicious” thyroid cytology, Cancer, 105, 492, 10.1002/cncr.21380 Kammori, 2000, Telomerase activity and telomere length in benign and malignant human thyroid tissues, Cancer Lett, 159, 175, 10.1016/S0304-3835(00)00547-4 Papotti, 2002, Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma, Eur J Endocrinol, 147, 515, 10.1530/eje.0.1470515 Orlandi, 2005, Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up, Thyroid, 15, 274, 10.1089/thy.2005.15.274 Bauer, 2004, Thyroid nodules and thyroid carcinoma in children Gharib, 1998, Thyroxine suppressive therapy in patients with nodular thyroid disease, Ann Intern Med, 128, 386, 10.7326/0003-4819-128-5-199803010-00008 Gharib, 1997, Changing concepts in the diagnosis and management of thyroid nodules, Endocrinol Metab Clin North Am, 26, 777, 10.1016/S0889-8529(05)70282-6 Giuffrida, 1995, Controversies in the management of cold, hot, and occult thyroid nodules, Am J Med, 99, 642, 10.1016/S0002-9343(99)80252-6 Scheumann, 1994, Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer, World J Surg, 18, 559, 10.1007/BF00353765 Welch Dinauer, 1998, Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults, Clin Endocrinol (Oxf), 49, 619, 10.1046/j.1365-2265.1998.00584.x Reiners, 2003, Differentiated thyroid cancer in childhood: pathology, diagnosis, therapy, Pediatr Endocrinol Rev, 1, 230 Vierhapper, 2005, Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders, Thyroid, 15, 1267, 10.1089/thy.2005.15.1267 Hodak, 2004, The calcitonin conundrum: is it time for routine measurement of serum calcitonin in patients with thyroid nodules?, J Clin Endocrinol Metab, 89, 511, 10.1210/jc.2003-031983 Martinetti, 2003, Evaluation of circulating calcitonin: analytical aspects, Tumori, 89, 566, 10.1177/030089160308900525 Papi, 2006, Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study, J Endocrinol Invest, 29, 427, 10.1007/BF03344126 Pacini, 2002, Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment, J Clin Endocrinol Metab, 87, 1499, 10.1210/jc.87.4.1499 Welch Dinauer, 1999, Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma, J Pediatr Surg, 34, 1799, 10.1016/S0022-3468(99)90316-0 Borson-Chazot, 2004, Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer, World J Surg, 28, 1088, 10.1007/s00268-004-7630-y Hayashi, 2004, Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma, Int J Oncol, 24, 89 Demidchik Iu, 2003, [Repeat surgery for recurrent thyroid cancer in children], Vopr Onkol, 49, 366 Powers, 2004, The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents, J Pediatr Endocrinol Metab, 17, 339, 10.1515/JPEM.2004.17.3.339 Powers, 2003, Tumor size and extent of disease at diagnosis predict the response to initial therapy for papillary thyroid carcinoma in children and adolescents, J Pediatr Endocrinol Metab, 16, 693, 10.1515/JPEM.2003.16.5.693 DeGroot, 1990, Natural history, treatment, and course of papillary thyroid carcinoma, J Clin Endocrinol Metab, 71, 414, 10.1210/jcem-71-2-414 Mazzaferri, 2000, Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy, Endocr Pract, 6, 469, 10.4158/EP.6.6.469 Samaan, 1992, The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients, J Clin Endocrinol Metab, 75, 714, 10.1210/jc.75.3.714 Chow, 2004, Differentiated thyroid carcinoma in childhood and adolescence–clinical course and role of radioiodine, Pediatr Blood Cancer, 42, 176, 10.1002/pbc.10410 Torres, 2001, Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects, J Clin Endocrinol Metab, 86, 1660, 10.1210/jc.86.4.1660 Lau, 2006, Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy, Intern Med J, 36, 564, 10.1111/j.1445-5994.2006.01149.x Baudin, 2003, Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients, J Clin Endocrinol Metab, 88, 1107, 10.1210/jc.2002-021365 Reynolds, 1993, Comparison of I-131 Absorbed radiation doses in children and adults: a tool for estimating therapeutic I-131 doses in children, 127 Kao, 1998, Stunning effects after a diagnostic dose of iodine-131, Nuklearmedizin, 37, 30 Leger, 1998, Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma, Eur J Nucl Med, 25, 242, 10.1007/s002590050223 Mandel, 2001, Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer, Clin Nucl Med, 26, 6, 10.1097/00003072-200101000-00002 Benua, 1986, A method and rationale for treating thyroid carcinoma with the largest safe dose of I-131, vol. II., 1317 Dorn, 2003, Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach, J Nucl Med, 44, 451 Sweeney, 2000, Radioiodine treatment of thyroid cancer, 155 Handelsman, 1983, Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer, Clin Endocrinol (Oxf), 18, 465, 10.1111/j.1365-2265.1983.tb02876.x Ahmed, 1984, Radioactive iodine and testicular damage, N Engl J Med, 311, 1576, 10.1056/NEJM198412133112414 Pacini, 1994, Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine, J Nucl Med, 35, 1418 Casara, 1993, Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations, Eur J Nucl Med, 20, 192, 10.1007/BF00169997 Balan, 1992, Outcome of pregnancy following treatment of well-differentiated thyroid cancer with 131iodine, Br J Obstet Gynaecol, 99, 1021, 10.1111/j.1471-0528.1992.tb13713.x Kulakov, 1993, Female reproductive function in areas affected by radiation after the Chernobyl power station accident, Environ Health Perspect, 101, 117, 10.1289/ehp.93101s2117 Lin, 1998, Outcome of pregnancy after radioactive iodine treatment for well differentiated thyroid carcinomas, J Endocrinol Invest, 21, 662, 10.1007/BF03350795 Schlumberger, 1995, Outcome of pregnancy in women with thyroid carcinoma, J Endocrinol Invest, 18, 150, 10.1007/BF03349727 Smith, 1994, Iodine 131 thyroid ablation in female children and adolescents: long-term risk of infertility and birth defects, Ann Surg Oncol, 1, 128, 10.1007/BF02303556 Biondi, 2005, Thyroid-hormone therapy and thyroid cancer: a reassessment, Nat Clin Pract Endocrinol Metab, 1, 32, 10.1038/ncpendmet0020 Toft, 2001, Clinical practice: subclinical hyperthyroidism, N Engl J Med, 345, 512, 10.1056/NEJMcp010145 Karga, 2004, Bone mineral density in hyperthyroidism, Clin Endocrinol (Oxf), 61, 466, 10.1111/j.1365-2265.2004.02110.x Mazzaferri, 2003, A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma, J Clin Endocrinol Metab, 88, 1433, 10.1210/jc.2002-021702 Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838 Rubino, 2003, Second primary malignancies in thyroid cancer patients, Br J Cancer, 89, 1638, 10.1038/sj.bjc.6601319 Powers, 2003, Treatment of recurrent papillary thyroid carcinoma in children and adolescents, J Pediatr Endocrinol Metab, 16, 1033, 10.1515/JPEM.2003.16.7.1033 Pacini, 2001, Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients, J Clin Endocrinol Metab, 86, 4092, 10.1210/jc.86.9.4092 Pineda, 1995, Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan, J Clin Endocrinol Metab, 80, 1488, 10.1210/jc.80.5.1488 Wang L, Robbins R, Feldman E, et al. Management of low measurable thyroglobulin (Tg) levels in thyroid cancer survivors who have negative whole body scans. Paper presented at the 76th Annual Meeting American Thyroid Association, Vancouver (BC), September 30–October 1, 2004. Pacini, 2003, Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma, J Clin Endocrinol Metab, 88, 3668, 10.1210/jc.2002-021925 Cailleux, 2000, Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?, J Clin Endocrinol Metab, 85, 175, 10.1210/jc.85.1.175 Mazzaferri, 2002, Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?, J Clin Endocrinol Metab, 87, 1490, 10.1210/jc.87.4.1490 Haugen, 2002, Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin, Thyroid, 12, 37, 10.1089/105072502753451959 Robbins, 2002, Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?, J Clin Endocrinol Metab, 87, 3242, 10.1210/jc.87.7.3242 Hoe, 2006, Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid carcinoma, J Pediatr Endocrinol Metab, 19, 25, 10.1515/JPEM.2006.19.1.25 Ceccarelli, 1988, Thyroid cancer in children and adolescents, Surgery, 104, 1143 Fenton, 2001, Thyroglobulin messenger ribonucleic acid levels in the peripheral blood of children with benign and malignant thyroid disease, Pediatr Res, 49, 429, 10.1203/00006450-200103000-00020 Ringel, 1999, Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma, J Clin Endocrinol Metab, 84, 4037, 10.1210/jc.84.11.4037 Helal, 2001, Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy, J Nucl Med, 42, 1464 Wang, 1999, [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels, J Clin Endocrinol Metab, 84, 2291, 10.1210/jc.84.7.2291 Antonelli, 2003, Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer, Thyroid, 13, 479, 10.1089/105072503322021142 Frattini, 2004, Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer, Oncogene, 23, 7436, 10.1038/sj.onc.1207980 Iorcansky, 2005, Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer, J Clin Endocrinol Metab, 90, 6553, 10.1210/jc.2005-1550 Robbins, 2002, A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation, J Nucl Med, 43, 1482 Pacini, 2002, Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal, J Clin Endocrinol Metab, 87, 4063, 10.1210/jc.2001-011918 Barbaro, 2003, Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation, J Clin Endocrinol Metab, 88, 4110, 10.1210/jc.2003-030298 Schlumberger, 1987, Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients, J Clin Endocrinol Metab, 65, 1088, 10.1210/jcem-65-6-1088 Vasyl Vasko, Andrew J, Bauer R, et al. Thyroid neoplasia in children. Basel (Switzerland): S. Karger AG; in press. Nikiforov, 1996, Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis, J Clin Endocrinol Metab, 81, 9, 10.1210/jc.81.1.9 Thomas, 1999, High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant, J Clin Endocrinol Metab, 84, 4232, 10.1210/jc.84.11.4232 Snijders, 2003, Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma, Oncogene, 22, 4281, 10.1038/sj.onc.1206621 Wreesmann, 2004, Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity, Genes Chromosomes Cancer, 40, 355, 10.1002/gcc.20049 McIver, 2004, The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma, Curr Drug Targets Immune Endocr Metabol Disord, 4, 221, 10.2174/1568008043339802 Foukakis, 2005, The ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPAR{gamma} fusion, J Clin Endocrinol Metab, 91, 1143, 10.1210/jc.2005-1372 Oertel, 2000, Medullary thyroid cancer, 383 Chi, 1998, Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia, Surg Oncol Clin N Am, 7, 681, 10.1016/S1055-3207(18)30240-0 Jensen, 1990, Thyroid cancer: a computer-assisted review of 5287 cases, Otolaryngol Head Neck Surg, 102, 51, 10.1177/019459989010200109 Manie, 2001, The RET receptor: function in development and dysfunction in congenital malformation, Trends Genet, 17, 580, 10.1016/S0168-9525(01)02420-9 Takahashi, 1987, ret transforming gene encodes a fusion protein homologous to tyrosine kinases, Mol Cell Biol, 7, 1378, 10.1128/MCB.7.4.1378 Learoyd, 1997, Genetic testing for familial cancer: consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2, Arch Surg, 132, 1022, 10.1001/archsurg.1997.01430330088015 Shimotake, 1996, Germline mutations of the RET proto-oncogene in pedigree with MEN type 2A: DNA analysis and its implications for pediatric surgery, J Pediatr Surg, 31, 779, 10.1016/S0022-3468(96)90131-1 Mulligan, 1993, Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A, Nature, 363, 458, 10.1038/363458a0 Zedenius, 1994, Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s, Hum Mol Genet, 3, 1259, 10.1093/hmg/3.8.1259 Wohllk, 1996, Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2, Endocrinol Metab Clin North Am, 25, 1, 10.1016/S0889-8529(05)70310-8 Eng, 1996, The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis, JAMA, 276, 1575, 10.1001/jama.1996.03540190047028 Selgas, 2004, On the epithelial-mesenchymal transition of mesothelial cells, Kidney Int, 66, 866, 10.1111/j.1523-1755.2004.814_2.x Cote, 2003, Lessons learned from the management of a rare genetic cancer, N Engl J Med, 349, 1566, 10.1056/NEJMe038148 Kaldrymides, 2006, A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening, Clin Endocrinol (Oxf), 64, 561, 10.1111/j.1365-2265.2006.02509.x Edery, 1994, Mutations of the RET proto-oncogene in Hirschsprung's disease, Nature, 367, 378, 10.1038/367378a0 Romeo, 1994, Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease, Nature, 367, 377, 10.1038/367377a0 Gagel, 1989, Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis, Ann Intern Med, 111, 802, 10.7326/0003-4819-111-10-802 Kousseff, 1991, Sipple syndrome with lichen amyloidosis as a paracrinopathy: pleiotropy, heterogeneity, or a contiguous gene?, J Am Acad Dermatol, 25, 651, 10.1016/0190-9622(91)70248-Z Hofstra, 1994, A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma, Nature, 367, 375, 10.1038/367375a0 Zedenius, 1995, Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas, J Clin Endocrinol Metab, 80, 3088, 10.1210/jc.80.10.3088 Raue, 1994, Multiple endocrine neoplasia type 2: clinical features and screening, Endocrinol Metab Clin North Am, 23, 137, 10.1016/S0889-8529(18)30121-X Eng, 1995, Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma, Clin Endocrinol (Oxf), 43, 123, 10.1111/j.1365-2265.1995.tb01903.x Gagel, 1995, Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A, J Intern Med, 238, 333, 10.1111/j.1365-2796.1995.tb01207.x Machens, 2005, Advances in the management of hereditary medullary thyroid cancer, J Intern Med, 257, 50, 10.1111/j.1365-2796.2004.01423.x Brandi, 2001, Guidelines for diagnosis and therapy of MEN type 1 and type 2, J Clin Endocrinol Metab, 86, 5658, 10.1210/jc.86.12.5658 Sansom, 1989, An assessment of the risks to the health of grazing animals from the radioactive contamination of pastures, Br Vet J, 145, 206, 10.1016/0007-1935(89)90072-9 Simon, 2002, Multiple endocrine neoplasia 2A syndrome: surgical management, J Pediatr Surg, 37, 897, 10.1053/jpsu.2002.32906 Frank-Raue, 2006, Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype, Eur J Endocrinol, 155, 229, 10.1530/eje.1.02216 Learoyd, 2005, Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations, Clin Endocrinol (Oxf), 63, 636, 10.1111/j.1365-2265.2005.02394.x Gagel, 1988, The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a: an 18-year experience, N Engl J Med, 318, 478, 10.1056/NEJM198802253180804 Ponder BA, Ponder MA, Coffey R, et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 20 1988;1(8582):397–401. Schuffenecker, 1998, Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs a Calcitonine, J Clin Endocrinol Metab, 83, 487, 10.1210/jc.83.2.487 Cohen, 2002, Gastrointestinal manifestations of multiple endocrine neoplasia type 2, Ann Surg, 235, 648, 10.1097/00000658-200205000-00006 Decker, 1998, Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene, J Pediatr Surg, 33, 207, 10.1016/S0022-3468(98)90433-X Decker, 1998, Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation, Hum Mol Genet, 7, 129, 10.1093/hmg/7.1.129 Duh, 1989, Medullary thyroid carcinoma: the need for early diagnosis and total thyroidectomy, Arch Surg, 124, 1206, 10.1001/archsurg.1989.01410100112019 Telander, 1985, Pediatric endocrine surgery, Surg Clin North Am, 65, 1551, 10.1016/S0039-6109(16)43786-2 O'Riordain, 1995, Multiple endocrine neoplasia type 2B: more than an endocrine disorder, Surgery, 118, 936, 10.1016/S0039-6060(05)80097-2 Wells, 1994, Lhermitte-Duclos disease and Cowden's syndrome in an adolescent patient. Case report, J Neurosurg, 81, 133, 10.3171/jns.1994.81.1.0133 Gagel, 1993, Clinical review 44: medullary thyroid carcinoma: recent progress, J Clin Endocrinol Metab, 76, 809, 10.1210/jc.76.4.809 Saad, 1984, Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients, Medicine (Baltimore), 63, 319, 10.1097/00005792-198411000-00001 Ball, 2000, Medullary Thyroid Carcinoma, 365 Gosnell, 2006, New era: prophylactic surgery for patients with multiple endocrine neoplasia-2a, ANZ J Surg, 76, 586, 10.1111/j.1445-2197.2006.03783.x Skinner, 2005, Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A, N Engl J Med, 353, 1105, 10.1056/NEJMoa043999 Heizmann, 2006, Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a, Eur J Surg Oncol, 32, 98, 10.1016/j.ejso.2005.10.007 Telander, 1994, Medullary thyroid carcinoma in children, Semin Pediatr Surg, 3, 188 Wang, 1999, Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma, J Clin Endocrinol Metab, 84, 4549, 10.1210/jc.84.12.4549 Lamb, 1999, Spuriously elevated plasma calcitonin in a patient with a thyroid nodule not associated with medullary thyroid carcinoma, Postgrad Med J, 75, 289, 10.1136/pgmj.75.883.289 Niccoli, 1997, Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group, J Clin Endocrinol Metab, 82, 338, 10.1210/jc.82.2.338 Ozgen, 1999, Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter, Thyroid, 9, 579, 10.1089/thy.1999.9.579 Vannelli, 1990, Insulin-like growth factor-I receptors in nonfunctioning thyroid nodules, J Clin Endocrinol Metab, 71, 1175, 10.1210/jcem-71-5-1175 Roelants, 2001, Usefulness of [99mTC]MIBI and [18F]fluorodeoxyglucose for imaging recurrent medullary thyroid cancer and hyperparathyroidism in MEN 2a syndrome, Acta Clin Belg, 56, 373, 10.1179/acb.2001.057 Carlomagno, 2002, ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases, Cancer Res, 62, 7284 Cohen, 2002, Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors, Surgery, 132, 960, 10.1067/msy.2002.128562 Croyle ML, Knauf JA, Traxler P, et al. Specific inhibition of kinase activity of ret-oncoproteins and of ret-induced cell growth by PKI166. Paper presented at the 84th Annual Meeting of the Endocrine Society.San Francisco (CA), June 19–22, 2002. Kikumori T, Hayashi H, Cote G. STI 571 (gleevec) inhibits growth of a human medullary thyroid carcinma cell line with an activating RET proto-oncogene mutation. Paper presented at the 8th International Workshop on MEN. Grand Rapids (MI), June 15–18, 2002. O'Doherty, 1998, Drug therapy alternatives in the treatment of thyroid cancer, Drugs, 55, 801, 10.2165/00003495-199855060-00007 Skinner, 2003, RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571, Anticancer Res, 23, 3601 Guba, 2002, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, 8, 128, 10.1038/nm0202-128 Strock C, Ball D, Denmeade S. RET tyrosine kinase inhibitors in medullary thyroid carcinoma. Paper presented at.the 8th International Workshop on MEN. Grand Rapids (MI), June 15–18, 2002. Traugott, 2005, Medullary thyroid cancer: medical management and follow-up, Curr Treat Options Oncol, 6, 339, 10.1007/s11864-005-0037-7 Yamazaki, 2002, Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12, Gene Ther, 9, 64, 10.1038/sj.gt.3301617